$COCP

H.C. Wainwright reiterated a Buy rating and $6.00 price target for Cocrystal Pharma (COCP), citing progress in its norovirus drug trial. The stock is up 15% premarket. COCP's Phase 1b study for CDI-988 is ongoing, with primary endpoints focused on efficacy against norovirus. Analysts have varying price targets, ranging from $8 to $10. COCP also announced a new board member, Carol L. Brosgart, effective August 12, 2026.

Cocrystal Pharma (COCP) appointed Robert Sapirstein as CEO, with a compensation package tied to performance and equity. Phillip Frost, chairman of OPKO Health (OPK), invested $5 million in COCP. The company's board includes notable figures with pharmaceutical and corporate experience. COCP's antiviral candidate, CDI-988, is in Phase 1b trials with FDA Fast Track designation, targeting norovirus and other viruses. The company has $7.1 million in cash, providing a runway until Q1 2024.

Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On August 12, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed Carol L. B

FROST PHILLIP MD ET AL purchased 75,000 indirectly-held shares of Cocrystal Pharma, Inc. (COCP) at $0.94 on 2026-08-03.

Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., August 3, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (N

Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001412486 0001412486 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001412486 0001412486 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants ...

$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants

$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants ...